Region:

Text Size

  • Smaller
  • Regular
  • Large

References

  1. NAGLAZYME [Prescribing Information]. Novato, CA: BioMarin; 2005.
  2. Giugliani R, Harmatz P, Wraith JE. Management guidelines for mucopolysaccharidosis VI. Pediatrics. 2007;120:405-418.
  3. Wilcox WR. Lysosomal storage disorders: the need for better pediatric recognition and comprehensive care. J Pediatr. 2004;144(5 Suppl):S3–S14.
  4. Swiedler SJ, Beck M, Bajbouj M, et al. Threshold effect of urinary glycosaminoglycans and the walk test as indicators of disease progression in a survey of subjects with Mucopolysaccharidosis VI (Maroteaux-Lamy syndrome). Am J Med Genet A. 2005;134:144–150.
  5. Neufeld EF, Muenzer J. The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease. Vol 3. New York, NY: McGraw-Hill; 2001:3421–3452. vol 3.
  6. Smith KS, Hallett KB, Hall RK, Wardrop RW, Firth N. Mucopolysaccharidosis: MPS VI and associated delayed tooth eruption. Int J Oral Maxillofac Surg. 1995;24:176–180.
  7. Harmatz P, Giugliani R, Schwartz I, et al. Enzyme replacement therapy for mucopolysaccharidosis VI: a Phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study. J Pediatr. 2006;148:533-539.
  8. Litjens T, Hopwood JJ. Mucopolysaccharidosis type VI: structural and clinical implications of mutations in N-acetylgalactosamine-4 sulfatase. Hum Mutat. 2001; 18:282–295.
  9. Gunin AG. Connective tissue [fact sheet]. Department of histology at the medical school of Chuvash State University. Available at: http://www.histol.chuvashia.com/tab-en/cont-en.htm. Accessed May 8, 2006.
  10. MPS I survey results: patterns in referral, diagnosis, and management of individuals with MPS I. National MPS society and Genzyme Corporation. April 2004. Available at: http://www.mpssociety.org/content/4067/Survey_Results/ Accessed: November 3, 2008.
  11. Heron D, Baumann C, Benichou JJ, Harpey JP, Le Merrer M. Early diagnosis of Maroteaux-Lamy syndrome in two patients with accelerated growth and advanced bone maturation. Eur J Pediatr. 2004;163:323-326.
  12. Lachman RS. Radiographic detection of mucopolysaccharidoses (MPS) BioMarin White Paper. A guide to understanding Maroteaux-Lamy Syndrome: Mucopolysaccharidosis (MPS) VI. The National MPS Society, Inc.
  13. Wraith JE. The mucopolysaccharidoses: a clinical review and guide to management. Arch Dis Childhood. 1995;72:263–267.
  14. Harmatz RP. Mucopolysaccharidosis type VI. Emedicine. December 18, 2006. Available at: http://www.Emedicine.com/PED/topic1373.htm Accessed: November 4, 2008.
  15. Harmatz P, Ketteridge D, Giugliani R, et al. Direct comparison of measures of endurance, mobility, and joint function during enzyme-replacement therapy of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): results after 48 weeks in a phase 2 open-label clinical study of recombinant human N-acetylgalactosamine 4-sulfatase. Pediatrics. 2005;115:e681–e689.
  16. Harmatz P, Giugliani R, Schwartz IV, Guffon N, Teles EL, Miranda MC, et al. Long-term follow-up of endurance and safety outcomes during enzyme replacement therapy for mucopolysaccharidosis VI: Final results of three clinical studies of recombinant human N-acetylgalactosamine 4-sulfastase. Mol Genet Metab. 2008. doi:10.1016/j.ymgme.2008.04.001.
  17. Lindeke LL, Leonard BJ, Presler B, Garwick A. Family-centered care coordination for children with special needs across multiple settings. J Pediatr Health Care. 2002;16:290-297.
  18. Holley UA. Social isolation: a practical guide for nurses assisting clients with chronic illness. Rehabil Nurs. 2007;32:51-56.
  19. Muenzer J, Fisher A. Advances in the Treatment of Mucopolysaccharidosis Type I. N Engl J Med. 2004;19:1932–1934.